Viking Therapeutics, Inc. ($VKTX)
Filing Information
| Accession Number | 0001193125-26-003116 |
|---|---|
| Form Type | 4 |
| Filing Date | Jan 6, 2026 |
| Document Date | Jan 2, 2026 |
| Document | View SEC Filing |
Transactions
7
Total Shares
221,710
Total Value
$1,896,969.39
P&L
+inf% (+$5,303,704.17)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Common Stock, par value $0.00001 per share | โ | Jan 2, 2026 | Grant/Award | 41,000 | $0.00 | $0.00 | 215,483 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock, par value $0.00001 per share | โ | Jan 2, 2026 | Grant/Award | 32,049 | $0.00 | $0.00 | 247,532 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock, par value $0.00001 per share | โ | Jan 5, 2026 | Sale | 31,961 | $32.30 | $1,032,180.50 | 215,571 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock, par value $0.00001 per share | โ | Jan 5, 2026 | Sale | 13,900 | $33.38 | $464,020.92 | 201,671 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock, par value $0.00001 per share | โ | Jan 5, 2026 | Sale | 10,300 | $34.24 | $352,634.92 | 191,371 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock, par value $0.00001 per share | โ | Jan 5, 2026 | Sale | 1,500 | $32.09 | $48,133.05 | 189,891 | Direct | โ | View Details | |
Chief Financial Officer | Stock Option (Right to Buy) | Derivative | Jan 2, 2026 | Grant/Award | 91,000 | $0.00 | $0.00 | 91,000 | Direct | โ | View Details |